The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
Verywell Health on MSN2d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant DepressionPeople with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
HealthDay on MSN8d
FDA Approves Spravato Nasal Spray for Treatment-Resistant DepressionWEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII ...
The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...
The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback